|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
combination therapy
oral tablet
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:atccode
|
L01 BC06
|
|
gptkbp:brand
|
gptkb:Xeloda
|
|
gptkbp:casnumber
|
154361-50-9
|
|
gptkbp:chemical_formula
|
C15 H22 N2 O6 S
|
|
gptkbp:class
|
pyrimidine analog
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
neoadjuvant therapy
palliative treatment
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe renal impairment
|
|
gptkbp:counseling_services
|
take with food
stay hydrated
avoid pregnancy during treatment
report severe side effects
follow-up appointments are important
|
|
gptkbp:developed_by
|
gptkb:Roche
|
|
gptkbp:dosage_form
|
twice daily
1250 mg/m2
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
capecitabine
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:leucovorin
gptkb:warfarin
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
renal function tests
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:mechanism_of_action
|
gptkb:oppression
|
|
gptkbp:metabolism
|
gptkb:5-fluorouracil
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibits DNA synthesis
peak plasma concentration
time to peak concentration
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
vomiting
diarrhea
thrombocytopenia
stomatitis
hand-foot syndrome
mucositis
|
|
gptkbp:targeted_cancer_type
|
metastatic cancer
adjuvant therapy
|
|
gptkbp:trade
|
gptkb:Xeloda
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Lapatinib
gptkb:trastuzumab
|
|
gptkbp:bfsLayer
|
6
|